Wave Life Sciences Ltd. (WVE)
Market Cap | 774.07M |
Revenue (ttm) | 112.91M |
Net Income (ttm) | -61.92M |
Shares Out | 122.46M |
EPS (ttm) | -0.52 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 763,285 |
Open | 5.93 |
Previous Close | 5.90 |
Day's Range | 5.82 - 6.33 |
52-Week Range | 3.15 - 7.67 |
Beta | -1.00 |
Analysts | Strong Buy |
Price Target | 12.29 (+96.33%) |
Earnings Date | May 9, 2024 |
About WVE
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for t... [Read more]
Financial Performance
In 2023, WVE's revenue was $113.31 million, an increase of 3005.10% compared to the previous year's $3.65 million. Losses were -$57.51 million, -64.46% less than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for WVE stock is "Strong Buy." The 12-month stock price forecast is $12.29, which is an increase of 96.33% from the latest price.
News
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
RestorAATion-2 clinical trial of WVE-006 in AATD patients underway; expected proof-of-mechanism data in patients with AATD remains on track for 2024
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
Appointment builds on Wave's recent progress advancing innovative genetic targets, such as INHBE, and continues to add significant experience to accelerate the rapid identification and translation of ...
Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024 Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNA...
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor...
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-s...
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satellite cells, which are important for potential muscle regeneration
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling d...
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
FORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024 Previous clinical proof-of-concept data demonstrated highest level of exon skipping ever observ...
Wave Life Sciences stock slides 31% after company prices $100 million secondary share offering
Wave Life Sciences Ltd.'s stock WVE, -30.57% tumbled 31% Thursday, after the clinical-stage pharma company priced a $100 million secondary share offering at $5 a share, or a discount over its closing ...
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling d...
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling d...
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
Wave Life Sciences Announces Initiation of Dosing in Clinical Trial Evaluating First-Ever RNA Editing Candidate, WVE-006, in Alpha-1 Antitrypsin Deficiency
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling d...
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
Initiated RestorAATion clinical program for WVE-006, industry's first-ever RNA editing clinical candidate, following approval of CTAs; dosing on track for 4Q 2023 and first-in-human proof-of-mechanism...
Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling d...
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
Presented preclinical proof-of-concept data for new, wholly owned program targeting INHBE for metabolic disorders, including obesity, which uses Wave's best-in-class GalNAc-siRNA capabilities and nove...
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling ...
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling ...
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
WVE-006 is the first-ever RNA editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitrypsin (AAT) protein and reduce ...
Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
Preparing for imminent submission of clinical trial applications (CTAs) for GalNAc-conjugated AATD candidate (WVE-006), the industry's first RNA editing clinical candidate